To the best of our knowledge, this is the first report showing that the expression of PTEN and PLK1 are companion biomarkers associated with an alternative therapeutic strategy and prognostic significance in human pancreatic cancer. This evidence concerns the gene PTEN and familial pancreatic carcinoma.